Shah M, Lingam H, Gao X, Gittleman H, et al. US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer. J Clin Oncol 2024 Feb 21:JCO2302112. doi: 10.1200/JCO.23.02112.
PMID: 38381994